NASDAQ, NLTX - Neoleukin Therapeutics Inc
We are a development stage biopharmaceutical company in the business of
commercially developing innovative products for the treatment of cardiovascular
diseases. Our lead compound is CD-NP, a chimeric natriuretic peptide currently
in Phase I clinical studies for the treatment of heart failure. We believe CD-NP
may be useful in several cardiovascular and renal indications. We are initially
developing CD-NP as a treatment for heart failure. We are also developing
2NTX-99, a pre-clinical, small molecule, anti-atherothrombotic agent with nitric
oxide (NO) donating properties.
We were incorporated in the State of Nevada on June 17, 1996 and reincorporated
in Delaware on February 9, 2007, at which time our name was SMI Products, Inc.,
or SMI. From inception through August 11, 2006, SMI was a development stage
company in the business of internet real estate mortgage services. On and after
August 11, 2006, SMI ceased its prior business. ...
Read SEC Filing on NASDAQ.com »